flumazenil + gabapentin

Flumazenil + gabapentin is a combination of two pharmaceutical agents, flumazenil and gabapentin, that has been investigated primarily for the treatment of substance dependence disorders such as alcohol and methamphetamine dependence. Flumazenil is a benzodiazepine receptor antagonist that acts by competitively inhibiting the benzodiazepine binding site on the GABA(A) receptor complex, thereby reversing or blocking the effects of benzodiazepines. Gabapentin is an anticonvulsant and antiepileptic drug that modulates voltage-gated calcium channels (specifically alpha-2-delta subunits), reducing excitatory neurotransmitter release. The combination has been studied in clinical trials for its potential to reduce withdrawal symptoms, craving, and relapse rates in patients with high alcohol withdrawal symptoms or stimulant dependence. While some studies have shown benefit in specific subgroups (e.g., those with high alcohol withdrawal), results are mixed and not universally positive[1][2][3][4][5]. The combination does not have regulatory approval as a fixed-dose product; both drugs are individually approved for other indications.